(Q44207366)

30 November 2017

Loss of response to levodopa in Parkinson's disease and co-occurrence with dementia: role of D3 and not D2 receptors (English)

1 reference

30 November 2017

0 references

1 reference

1 reference

J N Joyce

1

1 reference

30 November 2017

H L Ryoo

2

1 reference

30 November 2017

T B Beach

3

1 reference

30 November 2017

J N Caviness

4

1 reference

30 November 2017

Mark Stacy

5

1 reference

30 November 2017

E V Gurevich

6

1 reference

30 November 2017

Mark Reiser

7

1 reference

30 November 2017

C H Adler

8

1 reference

30 November 2017

language of work or name

English

0 references

publication date

1 November 2002

1 reference

30 November 2017

1 reference

30 November 2017

955

1 reference

30 November 2017

138-152

1 reference

30 November 2017

1-2

1 reference

Anterograde transport of brain-derived neurotrophic factor and its role in the brain.

30 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

[3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

Neuropathological stageing of Alzheimer-related changes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

Dopamine agonists: their role in the treatment of Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

Which factors predict cognitive decline in Parkinson's disease?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

Mesostriatal and mesolimbic dopamine uptake binding sites are reduced in Parkinson's disease and progressive supranuclear palsy: a quantitative autoradiographic study using [3H]mazindol.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

The relationship between dementia and direct involvement of the hippocampus and amygdala in Parkinson's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

Molecular diversity of the dopamine receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

Regional brain atrophy in progressive supranuclear palsy and Lewy body disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part I

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

Ageing and Parkinson's disease: substantia nigra regional selectivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

Diagnostic criteria for Parkinson disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

Midbrain dopaminergic cell loss in Parkinson's disease: computer visualization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

Dopamine D2 receptor density remains constant in treated Parkinson's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

The concept of the ventral striatum in nonhuman primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

Dopamine receptor properties in Parkinson's disease and Huntington's chorea evaluated by positron emission tomography using 11C-N-methyl-spiperone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

Biochemical aspects of Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

Clinico-pathological correlations in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine. III. Results in Parkinson's disease cases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

D2 but not D3 receptors are elevated after 9 or 11 months chronic haloperidol treatment: influence of withdrawal period

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson's, Alzheimer's with parkinsonism, and Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

The zitter mutant rat exhibits loss of D3 receptors with degeneration of the dopamine system.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

A paradoxical regulation of the dopamine D3 receptor expression suggests the involvement of an anterograde factor from dopamine neurons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

Motor activity following the administration of selective D-1 and D-2 dopaminergic drugs to MPTP-treated common marmosets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

Characterization of (125)I-IABN, a novel azabicyclononane benzamide selective for D2-like dopamine receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

Correlation between neuromorphometry in the substantia nigra and clinical features in Parkinson's disease using disector counts.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

The Frequency and Associated Risk Factors for Dementia in Patients With Parkinson's Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

[123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

Specific A10 dopaminergic nuclei in the midbrain degenerate in Parkinson's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part II.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

Damage to dopamine systems differs between Parkinson's disease and Alzheimer's disease with parkinsonism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

[123I]beta-CIT SPECT visualizes dopamine transporter loss in de novo parkinsonian patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

The neural mechanisms and progressive nature of symptoms of Parkinson's disease--based on clinical, neurophysiological and morphological studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

The dopamine D2 agonist LY 141865, but not the D1 agonist SKF 38393, reverses parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

Reduced expression of brain-derived neurotrophic factor protein in Parkinson's disease substantia nigra.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

Dopaminergic activities in the human striatum: rostrocaudal gradients of uptake sites and of D1 and D2 but not of D3 receptor binding or dopamine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

Expression of D(3) receptor messenger RNA and binding sites in monkey striatum and substantia nigra after nigrostriatal degeneration: effect of levodopa treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

Lewy bodies are located preferentially in limbic areas in diffuse Lewy body disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

Striatal uptake of a novel PET ligand, [18F]?-CFT, is reduced in early Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

A post-mortem study on striatal dopamine receptors in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

Convergence of Lewy bodies and neurofibrillary tangles in amygdala neurons of Alzheimer's disease and Lewy body disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

Antecedent clinical features associated with dementia in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

Drug-naive patients with Parkinson's disease in Hoehn and Yahr stages I and II show a bilateral decrease in striatal dopamine transporters as revealed by [123I]beta-CIT SPECT.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

The pedunculopontine nucleus in Parkinson's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903396-6

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0006-8993(02)03396-6

1 reference

30 November 2017

1 reference